{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:32:14Z","timestamp":1766503934203,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00330-021-08388-6","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T12:02:48Z","timestamp":1638187368000},"page":"3085-3096","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Optimization of whole-body 2-[18F]FDG-PET\/MRI imaging protocol for the initial staging of patients with myeloma"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9802-8583","authenticated-orcid":false,"given":"Robert","family":"Burns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Mul\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Blanc-Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojdeh","family":"Tofighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Belhadj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Le Bras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Baranes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"8388_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3324\/haematol.10554","volume":"92","author":"E Zamagni","year":"2007","unstructured":"Zamagni E, Nanni C, Patriarca F et al (2007) A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92:50\u201355","journal-title":"Haematologica"},{"key":"8388_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00256-006-0127-z","volume":"35","author":"RJ Breyer","year":"2006","unstructured":"Breyer RJ, Mulligan ME, Smith SE, Line BR, Badros AZ (2006) Comparison of imaging with FDG PET\/CT with other imaging modalities in myeloma. Skeletal Radiol 35:632\u2013640","journal-title":"Skeletal Radiol"},{"key":"8388_CR3","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00277-009-0829-0","volume":"88","author":"S L\u00fctje","year":"2009","unstructured":"L\u00fctje S, de Rooy JWJ, Croockewit S, Koedam E, Oyen WJG, Raymakers RA (2009) Role of radiography, MRI and FDG-PET\/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol 88:1161\u20131168","journal-title":"Ann Hematol"},{"key":"8388_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/sj.thj.6200312","volume":"4","author":"BGM Durie","year":"2003","unstructured":"Durie BGM, Kyle RA, Belch A et al (2003) Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J 4:379\u2013398","journal-title":"Hematol J"},{"key":"8388_CR5","doi-asserted-by":"crossref","unstructured":"Cavo M, Terpos E, Nanni C et al (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749\u2013757","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"8388_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/annonc\/mdi362","volume":"16","author":"LA Moulopoulos","year":"2005","unstructured":"Moulopoulos LA, Gika D, Anagnostopoulos A et al (2005) Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 16:1824\u20131828","journal-title":"Ann Oncol"},{"key":"8388_CR7","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s11547-013-0946-7","volume":"118","author":"GL Cascini","year":"2013","unstructured":"Cascini GL, Falcone C, Console D et al (2013) Whole-body MRI and PET\/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study. Radiol Med 118:930\u2013948","journal-title":"Radiol Med"},{"key":"8388_CR8","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C et al (2011) Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118:5989\u20135995","journal-title":"Blood"},{"key":"8388_CR9","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","volume":"28","author":"J Hillengass","year":"2010","unstructured":"Hillengass J, Fechtner K, Weber M-A et al (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28:1606\u20131610","journal-title":"J Clin Oncol"},{"key":"8388_CR10","doi-asserted-by":"crossref","unstructured":"Cavo M, Terpos E, Nanni C et al (2017) Review role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18:e206\u2013e2017","DOI":"10.1016\/S1470-2045(17)30189-4"},{"key":"8388_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1148\/radiol.10091809","volume":"257","author":"K Fechtner","year":"2010","unstructured":"Fechtner K, Hillengass J, Delorme S et al (2010) Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology 257:195\u2013204","journal-title":"Radiology"},{"key":"8388_CR12","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV et al (2019) International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20:e302\u2013e312","journal-title":"Lancet Oncol"},{"key":"8388_CR13","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D et al (2017) Prospective evaluation of magnetic resonance imaging and [18 F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 Tri. J Clin Oncol 35:2911\u20132918","journal-title":"J Clin Oncol"},{"key":"8388_CR14","doi-asserted-by":"crossref","unstructured":"Koutoulidis V, Fontara S, Terpos E et al (2017) Quantitative diffusion-weighted imaging of the bone marrow: an adjunction tool for the diagnosis of a diffuse mr imaging pattern in patients with multiple myeloma. Radiology 282:484\u2013493","DOI":"10.1148\/radiol.2016160363"},{"key":"8388_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1148\/radiol.13131529","volume":"271","author":"SL Giles","year":"2014","unstructured":"Giles SL, Messiou C, Collins DJ et al (2014) Whole-body diffusion-weighted MR imaging for assessment of Treatment response in Myeloma. Radiology 271:785\u2013794","journal-title":"Radiology"},{"key":"8388_CR16","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/leu.2010.70","volume":"24","author":"LA Moulopoulos","year":"2010","unstructured":"Moulopoulos LA, Dimopoulos MA, Christoulas D et al (2010) Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia 24:1206\u20131212","journal-title":"Leukemia"},{"key":"8388_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/jmri.20349","volume":"22","author":"S Nos\u00e0s-Garcia","year":"2005","unstructured":"Nos\u00e0s-Garcia S, Moehler T, Wasser K et al (2005) Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. J Magn Reson Imaging 22:154\u2013162","journal-title":"J Magn Reson Imaging"},{"key":"8388_CR18","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1148\/radiol.2503081017","volume":"250","author":"C Lin","year":"2009","unstructured":"Lin C, Luciani A, Belhadj K et al (2009) Patients with plasma cell disorders examined at whole-body dynamic contrast-enhanced MR imaging: initial experience. Radiology 250:905\u2013915","journal-title":"Radiology"},{"key":"8388_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1148\/radiol.09090629","volume":"254","author":"C Lin","year":"2010","unstructured":"Lin C, Luciani A, Belhadj K et al (2010) Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. Radiology 254:521\u2013531","journal-title":"Radiology"},{"key":"8388_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1148\/radiol.2019181949","volume":"291","author":"C Messiou","year":"2019","unstructured":"Messiou C, Hillengass J, Delorme S et al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology 291:5\u201313","journal-title":"Radiology"},{"key":"8388_CR21","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548","journal-title":"Lancet Oncol"},{"key":"8388_CR22","doi-asserted-by":"crossref","unstructured":"Filonzi G, Mancuso K, Zamagni E et al (2017) A comparison of different staging systems for multiple myeloma: can the MRI pattern play a prognostic role? AJR Am J Roentgenol 209:152\u2013158","DOI":"10.2214\/AJR.16.17219"},{"key":"8388_CR23","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1148\/rg.2019180096","volume":"39","author":"AG Ormond Filho","year":"2019","unstructured":"Ormond Filho AG, Carneiro BC, Pastore D et al (2019) Whole-body imaging of multiple myeloma: diagnostic criteria. Radiographics 39:1077\u20131097","journal-title":"Radiographics"},{"key":"8388_CR24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00256-017-2609-6","volume":"46","author":"JC Dutoit","year":"2017","unstructured":"Dutoit JC, Verstraete KL (2017) Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. Skeletal Radiol 46:733\u2013750","journal-title":"Skeletal Radiol"},{"key":"8388_CR25","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1007\/s00330-018-5796-1","volume":"29","author":"A Larbi","year":"2019","unstructured":"Larbi A, Omoumi P, Pasoglou V et al (2019) Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences. Eur Radiol 29:4503\u20134513","journal-title":"Eur Radiol"},{"key":"8388_CR26","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00330-019-06469-1","volume":"30","author":"FE Lecouvet","year":"2020","unstructured":"Lecouvet FE, Boyadzhiev D, Collette L et al (2020) MRI versus 18F-FDG-PET\/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance. Eur Radiol 30:1927\u20131937","journal-title":"Eur Radiol"},{"key":"8388_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174","journal-title":"Biometrics"},{"key":"8388_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s11604-018-0738-z","volume":"36","author":"MAA Basha","year":"2018","unstructured":"Basha MAA, Hamed MAG, Refaat R et al (2018) Diagnostic performance of 18F-FDG PET\/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study. Jpn J Radiol 36:382\u2013393","journal-title":"Jpn J Radiol"},{"key":"8388_CR29","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/leu.2015.338","volume":"30","author":"C Pawlyn","year":"2016","unstructured":"Pawlyn C, Fowkes L, Otero S et al (2016) Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia 30:1446\u20131448","journal-title":"Leukemia"},{"key":"8388_CR30","first-page":"479","volume":"5","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Mosebach J, Freitag MT et al (2015) Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. Am J Nucl Med Mol Imaging 5:479\u2013492","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"8388_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/leu.2013.244","volume":"28","author":"J Hillengass","year":"2014","unstructured":"Hillengass J, Weber MA, Kilk K et al (2014) Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukemia 28:174\u2013178","journal-title":"Leukemia"},{"key":"8388_CR32","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114:2068\u20132076","journal-title":"Blood"},{"key":"8388_CR33","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2967\/jnumed.113.131169","volume":"55","author":"C Ho","year":"2014","unstructured":"Ho C, Chen S, Leung YL et al (2014) 11C-acetate PET\/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET\/CT. J Nucl Med 55:749\u2013752","journal-title":"J Nucl Med"},{"key":"8388_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00259-013-2520-x","volume":"41","author":"C Lin","year":"2014","unstructured":"Lin C, Ho C-L, Ng S-H et al (2014) (11)C-acetate as a new biomarker for PET\/CT in patients with multiple myeloma: initial staging and postinduction response assessment. Eur J Nucl Med Mol Imaging 41:41\u201349","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8388_CR35","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjh.12820","volume":"165","author":"M-K Song","year":"2014","unstructured":"Song M-K, Chung J-S, Lee J-J et al (2014) Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation. Br J Haematol 165:777\u2013785","journal-title":"Br J Haematol"},{"key":"8388_CR36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1365-2141.2011.08658.x","volume":"153","author":"J Hillengass","year":"2011","unstructured":"Hillengass J, B\u00e4uerle T, Bartl R et al (2011) Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol 153:721\u2013728","journal-title":"Br J Haematol"},{"key":"8388_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00259-019-04452-y","volume":"47","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer ME, Prosch H, Beer L et al (2020) PET\/MRI versus PET\/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging 47:51\u201360","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8388_CR38","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1007\/s00259-019-04402-8","volume":"46","author":"A Morsing","year":"2019","unstructured":"Morsing A, Hildebrandt MG, Vilstrup MH et al (2019) Hybrid PET\/MRI in major cancers: a scoping review. Eur J Nucl Med Mol Imaging 46:2138\u20132151","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-08388-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-021-08388-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-08388-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T15:11:12Z","timestamp":1650899472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-021-08388-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["8388"],"URL":"https:\/\/doi.org\/10.1007\/s00330-021-08388-6","relation":{},"ISSN":["1432-1084"],"issn-type":[{"type":"electronic","value":"1432-1084"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"6 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Robert Burns.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Two of the authors (Robert Burns and S\u00e9bastien Mul\u00e9) have significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and Biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Institutional Review Board approval was obtained. (CERIM, approval number CRM-1912\u2013048).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"\u2022 retrospective\u2022 diagnostic study\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}